159858-22-7

Basic information

• Product Name: FMoc-Val-Cit-PAB
• Synonyms: FMoc-Val-Cit-PAB
• CAS NO: 159858-22-7
• Molecular Formula: C₃₃H₃₉N₅O₆
• Molecular Weight: 601.69
• Mol File: 159858-22-7.mol
• Article Data: 28

Chemical Properties

• Melting Point: 204 °C(dec.)
• Boiling Point: 914.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.276±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 10.63±0.46(Predicted)
• CAS DataBase Reference: FMoc-Val-Cit-PAB(CAS DataBase Reference)
• NIST Chemistry Reference: FMoc-Val-Cit-PAB(159858-22-7)
• EPA Substance Registry System: FMoc-Val-Cit-PAB(159858-22-7)

Safety Data

• Hazardous Substances Data: 159858-22-7(Hazardous Substances Data)

Usage

Description

FMoc-Val-Cit-PAB-OH is a cleavable linker used in the development of antibody-drug conjugates (ADCs). It is designed to facilitate the targeted delivery of therapeutic agents to cancer cells, ensuring that the drug payload is released only within the lysosome of the target cell. The linker is composed of Fmoc (9-fluorenylmethoxycarbonyl), Val (valine), Cit (citrulline), and PAB (para-aminobenzyloxycarbonyl), with the Fmoc group being deprotected under basic conditions. The Val-Cit sequence is specifically cleaved by the enzyme Cathepsin B, which is predominantly found in the lysosome, ensuring the selective release of the ADC payload.

Uses

Used in Pharmaceutical Industry:
FMoc-Val-Cit-PAB is used as a cleavable ADC linker for the targeted delivery of therapeutic agents to cancer cells. The application reason is that the Val-Cit sequence is specifically cleaved by Cathepsin B, an enzyme present in the lysosome, ensuring the selective release of the ADC payload within the target cell. This targeted approach minimizes damage to healthy cells and enhances the therapeutic efficacy of the drug.
Additionally, the Fmoc group can be deprotected under basic conditions, allowing for the controlled release of the drug payload and further customization of the ADC for specific applications.

Upstream product

• 159858-21-6 (S)-2-((S)-2-((((9H-fluoren-9-yl)-methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid 
• 623-04-1 4-aminobenzenemethanol 
• 68858-20-8 Fmoc-Val-OH 
• 130878-68-1 2,5-dioxopyrrolidin-1-yl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valinate 
• 1037794-22-1 (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide 
• 1037793-80-8 (S)-tert-butyl 1-(4-(hydroxymethyl)phenylamino)-1-oxo-5-ureidopentan-2-ylcarbamate 
• 372-75-8 Citrulline 
• 133174-15-9 (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid 
• 870487-04-0 (S)-(9H-fluoren-9-yl)methyl (1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate 
• 6692-89-3 N^α-benzyloxy-carbonyl-L-citrulline 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Downstream Products

• 159857-79-1 (2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-N-[4-(hydroxymethyl)phenyl]-5-ureidopentanamide 
• 863971-53-3 (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((S)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate 
• 1611498-13-5 C₂₉H₄₂N₆O₁₁S₂ 
• 1611498-14-6 C₃₆H₄₅N₇O₁₅S₂ 
• 159857-80-4 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide 
• 159857-81-5 N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N⁵-carbamoyl-N[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-ornithinamide 

Relevant articles and documents

Linker, Antibody-Drug Conjugate Including Same and Use Thereof

Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.

CYCLIC DINUCLEOTIDE STING AGONISTS TETHERED TO A PD-1 OR CTLA-4 ANTIBODIES

Disclosed are antibody-drug conjugates and compositions thereof for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin E

In recent years, several antibody drug conjugates (ADC) have been accepted by the FDA as therapeutics against cancer. It is well-known that control of drug-to-antibody ratio (DAR) is vital for the success of an ADC, which inspires the advancement of bette